Most of the retatrutide conversation in Australia is about one number: how much weight comes off. But there's a quieter question that matters just as much for anyone who eventually uses a triple-agonist here — how much of that loss is fat, and how much is muscle? If you're following retatrutide Australia news while you wait for the TGA, body composition is the topic worth understanding now, because it's the part you can actually influence before a script ever exists.

Retatrutide remains investigational. It is not TGA-approved, and Eli Lilly has said it plans to begin regulatory filings from 2027 (its US biologics licence application is flagged for the first quarter of 2027). Nothing below is a treatment plan — it's a plain-English read of what the science does and doesn't show.

Why muscle is the live scientific question with retatrutide

Retatrutide hits three receptors: GLP-1, GIP and glucagon. That third one is what separates it from semaglutide (Ozempic, Wegovy — one receptor) and tirzepatide (Mounjaro, Zepbound — two). Glucagon receptor activity is a big part of why the weight loss numbers are so large — TRIUMPH-1 reported up to roughly 28.3% average body weight reduction at the 12mg dose over 80 weeks, with 45.3% of participants losing at least 30% of their body weight.

But chronic glucagon receptor activation has a theoretical downside that researchers have flagged openly: it can reduce circulating amino acids, which could in principle dial down muscle protein synthesis. That's not a scare story — it's a mechanism-level hypothesis that had to be tested rather than assumed. More on how the three receptors work in our what is retatrutide explainer.

What the body composition data actually showed

The most useful published evidence so far is a substudy of the phase 2 trial in people with type 2 diabetes, published in The Lancet Diabetes & Endocrinology in 2025. Using body composition imaging, it found retatrutide produced significantly greater reductions in total body fat mass than both placebo and dulaglutide — and, importantly, that the proportion of weight loss coming from lean mass was broadly similar to what's seen with other obesity treatments.

Two honest caveats. First, this was a phase 2 substudy in people with type 2 diabetes over 36 weeks, not a phase 3 population followed for 80 weeks or more — so it doesn't automatically translate to the much deeper weight losses seen in TRIUMPH-1. Second, "similar proportion of lean mass loss" is reassuring relative to existing drugs, but when total weight loss is far larger, the absolute kilograms of lean tissue lost can still be meaningful. Bigger loss means more of everything comes off.

The blunt summary: current evidence does not show retatrutide is unusually muscle-wasting compared with GLP-1 medicines already on the market. It also doesn't yet give us long, phase 3, DXA-confirmed answers at the highest doses. Both things are true at once. We track new readouts as they publish on our clinical trials page.

Retatrutide Australia: why body composition has a local edge

Here's where it genuinely matters for Australians rather than being a forced angle. Around 66.8% of Australian adults are overweight or obese, and a large share of the people most likely to be prescribed a triple-agonist when it eventually arrives are in their 50s, 60s and beyond — the exact age band where age-related muscle loss (sarcopenia) is already underway. Losing 25–30% of body weight is transformative for knees, sleep, blood pressure and diabetes risk; losing strength and functional capacity alongside it is not.

The practical Australian implication is about preparation, not the drug. Australia's physical activity guidelines already ask adults to do muscle-strengthening activity on at least two days a week — a target most adults don't hit. If retatrutide clears the TGA and reaches Australian pharmacies from the late 2020s, the people who arrive with an established resistance-training habit and a dietitian in their corner are the ones best placed to make the weight that comes off be fat.

Things that are within your control right now

  • Start resistance training before you need it. Two sessions a week, whole-body, progressive. It's the single most evidence-backed lever for protecting lean mass during any weight loss.
  • Get your protein sorted. Dietitians routinely recommend higher protein intake spread across meals during rapid weight loss. Note this advice comes from general weight-management practice, not from retatrutide trials — no retatrutide trial has tested a specific protein target.
  • Ask about a GP-coordinated care plan. Australians with chronic conditions may be able to access Medicare-subsidised allied health visits, including dietitians, through their GP. Worth asking about now, not in 2028.
  • Know your baseline. Weight alone tells you very little. A starting point for strength and function makes any future change interpretable.

More on the local regulatory picture in our Australia hub, and on tolerability in our safety section — the most commonly reported adverse events across the trials have been gastrointestinal: diarrhoea, nausea, constipation and decreased appetite.

What to watch next

Full phase 3 body composition analyses from the TRIUMPH programme are the readout to watch — ideally imaging-confirmed data at the higher doses over 80 weeks and beyond, published in a peer-reviewed journal rather than announced in a release. Until that lands, treat any confident claim about retatrutide and muscle — in either direction — as running ahead of the evidence.

Join the free updates list and we'll email you when phase 3 body composition data publishes and when anything moves at the TGA.

FAQ

Does retatrutide cause muscle loss?

All substantial weight loss involves some lean mass loss, and retatrutide is no exception. A phase 2 substudy published in The Lancet Diabetes & Endocrinology found retatrutide reduced fat mass significantly more than placebo or dulaglutide, with the proportion of lean mass loss similar to other obesity treatments — but full phase 3 body composition data at the highest doses is still awaited.

Is retatrutide available in Australia in 2026?

No. Retatrutide is investigational and has not been approved by the TGA. Eli Lilly has indicated it plans to begin regulatory filings from 2027, and any Australian approval would follow a TGA review after that.

How can I protect muscle while losing weight?

The consistent, evidence-backed levers are regular resistance training and adequate protein intake spread across the day, ideally with professional guidance. Speak to your GP or an Accredited Practising Dietitian about what's appropriate for you — this is general information, not a personalised plan.

How does retatrutide differ from Ozempic and Mounjaro?

Ozempic and Wegovy contain semaglutide, which targets one receptor (GLP-1). Mounjaro and Zepbound contain tirzepatide, which targets two (GLP-1 and GIP). Retatrutide targets three — adding glucagon — which is thought to drive both its larger weight loss and the extra interest in its body composition effects.

Sources

Disclaimer: retatrutide.net.au is an independent Australian information site and is not affiliated with, endorsed by or sponsored by Eli Lilly. Retatrutide is an investigational medicine and is not approved by the TGA. This article is general information only and is not medical advice, diagnosis or treatment. Always speak with your GP or another qualified health professional about your individual circumstances.